Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epizyme has entered into an agreement with GlaxoSmithKline (GSK) for the discovery, development and marketing of new small molecule therapeutics for the treatment of cancer and other diseases targeting histone methyltransferases (HMTs).
Subscribe to our email newsletter
As per the agreement, GSK will pay research funding as well as a sum of $20m as an upfront payment to Epizyme.
Additionally, GSK is also responsible to pay a sum of more than $630m in total milestone payments if medicines are commercialized for all targets in the collaboration.
Epizyme will be primarily responsible for research up to development candidate selection, and GSK will be solely responsible for development and commercialization.
Epizyme president and CEO Robert Gould said that Epizyme’s mission is to develop personalized therapeutics for genetically-defined patients based on their understanding of the driving role played by many HMTs in human disease.
"This collaboration validates our discovery platform and the targeted approach we bring to HMT therapeutics," Gould said.